

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 103 252 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**12.03.2003 Bulletin 2003/11**

(51) Int Cl.7: **A61K 9/16**

(21) Application number: **99931261.4**

(86) International application number:  
**PCT/ES99/00230**

(22) Date of filing: **20.07.1999**

(87) International publication number:  
**WO 00/004881 (03.02.2000 Gazette 2000/05)**

**(54) PHARMACEUTICAL ORAL PREPARATION OF A COMPOUND HAVING AN ANTIFUNGIC  
ACTIVITY, AND PREPARATION METHOD**

ORALE PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN WIRKSTOFF MIT  
ANTIMYKOTISCHER WIRKUNG UND VERFAHREN ZU IHRER HERSTELLUNG

PREPARATION PHARMACEUTIQUE ORALE D'UN COMPOSE A ACTIVITE ANTIFONGIQUE ET  
SON PROCEDE DE PREPARATION

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(73) Proprietor: **Liconsa, Liberacion Controlada de  
Sustancias Activas, S.A.**  
**08028 Barcelona (ES)**

(30) Priority: **21.07.1998 ES 9801539**

(72) Inventor: **PICORNELL DARDER, Carlos**  
**E-28002 Madrid (ES)**

(43) Date of publication of application:  
**30.05.2001 Bulletin 2001/22**

(74) Representative: **Ponti Sales, Adelaida et al**  
**C. Consell de Cent, 322**  
**08007 Barcelona (ES)**

(56) References cited:  
**WO-A-98/00116 WO-A-98/42318**

**EP 1 103 252 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## Description

[0001] The present invention relates to an oral pharmaceutical composition comprising a compound having antifungal activity and in which the problems of low bioavailability, due to the poor solubility of antifungal compounds in an aqueous medium, are solved.

[0002] The present invention also relates to a method for obtaining said oral pharmaceutical composition that has advantages over conventional methods.

## Background of the invention

[0003] The problems of solubility associated to the chemical structures of azoles such as itraconazole and saperconazole, compounds respectively described in US patents 4,267,179 and 4,916,134, try to be solved by preparing different pharmaceutical forms on the base of the different administration methods.

[0004] It is known that the solubility of a compound can increase when it is added to an hydrophilic polymer and apply the mixture on an inert core. A formulation is obtained that improves remarkably the bioavailability of the compound.

[0005] In patent EP 658103 (published in Spain as ES 2097536 T3) pellets of itraconazole and saperconazole prepared on the basis of this technology. It discloses the preparation of a solution in ethanol and methylene chloride of the antifungal compound and the hydrophilic polymer hydroxypropylmethylcellulose (HPMC) which is sprayed in a fluidized bed on inert cores having a size between 600 and 700  $\mu\text{m}$ . Once the spraying process is finished, the beads are dried in the same apparatus during ten minutes at a temperature of 50-55°C, but thereafter they must be introduced in a vacuum drier for about 36 hours at a temperature of 80°C. The dry cores are sieved and are subjected to a second coating process in order to form a second layer with a solution of polyethylene glycol 20000 (PEG 20000) in a fluidized bed. When the process is finished, the beads are dried in the apparatus for 10 minutes at 50-55°C and then dry air at 20-25°C is supplied to them during 5-15 minutes. When the drying process is finished, they are stored in suitable containers.

[0006] EP 658103 teaches that the second coating layer with PEG 20000, which is a sealing coating layer, is applied in order to prevent pellets from adhering, and that it is necessary to have inert cores of a size between 600 and 700  $\mu\text{m}$  in order to avoid drying problems and pellet aggregation. According to EP 658103, inert cores having a larger size involve a smaller specific surface, whereby the coating layers need to be very thick and thus difficult to dry, while if the inert core size is too small it gives rise to a thin coating layer, easy to dry but that can undergo agglomeration phenomena during the coating step.

## Description of the Invention

[0007] The present invention provides an oral pharmaceutical formulation and a working method that allow to solve the problems of solubility, drying and bioavailability of pellets of antifungal compounds.

[0008] The new formulation object of the present invention is characterized in that it consists of spherical beads comprising an inert core coated with a single layer of active charge comprising an antifungal compound. The process of coating the inert cores is carried out by spraying a solution of antifungal compound.

[0009] The oral pharmaceutical composition of the present invention comprises:

- a/ an inert core
- b/ a soluble active layer obtained from a solution comprising:

- an active principle having antifungal activity selected between Itracorazole and Saperconazole
- an hydrophilic polymer
- a non-ionic surfactant.

[0010] The active principles having antifungal activity included in the scope of the present invention are itraconazole, ( $\pm$ )-*cis*-4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1*H*-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3*H*-1,2,4-triazol-3-one, and saperconazole, ( $\pm$ )-*cis*-4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1*H*-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3*H*-1,2,4-triazol-3-one.

[0011] The inert cores are neutral spherical microbeads which can have in their composition one or more of the following substances: sorbitol, mannitol, saccharose, starch, microcrystalline cellulose, lactose, glucose, trehalose, maltitol and fructose. Their size is comprised between 50-600  $\mu\text{m}$ , preferably between 500-600  $\mu\text{m}$ .

[0012] In the present invention, the solution to be sprayed on inert cores is formed by the active principle having antifungal activity, dissolved in a mixture of organic solvents formed by ethanol and methylene chloride, in which the hydrophilic polymer is dissolved, and a surfactant.

[0013] The hydrophilic polymer is selected among the group comprising HPMC, hydroxypropylcellulose (HPC), polyvinyl pyrrolidone (PVP), methacrylates, etc. The weight to weight ratio (w/w) between the antifungal agent and the polymer is in the range [(1:1) - (1:3)].

[0014] The non-ionic surfactant is selected from propylene glycol esters, glycerol esters, (mono-di-tri-) acetylated sorbitan, (mono, di-tri) acetylated saccharose, polyoxyethylene sorbitan esters of fatty acids, polyoxyethylene alkyl ethers of fatty chain, polyoxyeth-

ylene-polyoxypropylene copolymers.. etc. The weight to weight ratio between the antifungal agent and the surfactant lies within the range [(1.5:1)-(29:1)].

[0015] Another object of the present invention is a method for manufacturing the Galenic formulations of the invention.

[0016] In the following the method is described, paying special attention to the proportions of each component and the methodology used.

[0017] In a stainless steel tank of suitable size, ethanol and methylene chloride (65:35) (w/w) is mixed. The antifungal compound (2.8% - 5.0%) (w/w), the hydrophilic polymer (3.5% - 6.3%) (w/w) and the surfactant (0.2% - 2.0%) (w/w) are added.

[0018] Thereafter the coating solution is sprayed to obtain a single layer on the neutral pellets having a size comprised between 50 and 600  $\mu\text{m}$ , preferably 500-600  $\mu\text{m}$ , in a fluidized bed. During the whole process the spraying speed is constant and the temperature is maintained at 45°C.

[0019] When the coating step is finished, the pellets are kept in the apparatus for 15 minutes at a temperature of 45°C, this being the last drying step.

[0020] This technology allows to work with inert cores of a size between 50 and 600  $\mu\text{m}$ , which is smaller than that claimed in EP 658103 and which favours the coating process due to the increase of specific surface; surprisingly, this size does not give rise to any agglomeration problem, and further the layer of PEG 20000 sealing coating is not necessary, because the incorporation of the non-ionic surfactant surprisingly prevents particle agglomeration.

[0021] With the present invention the cost of the process is reduced by a reduction in time and in use of the apparatus, and at the same time the final drying of the beads is favoured, thus minimizing the risk of non fulfilment of the Proper Manufacturing Standards.

[0022] The present invention uses a fluidized bed in which the coating process is carried out. It is not necessary to use a second apparatus to dry the coated beads: on the contrary, a short drying step (15 minutes at 45°C), carried out in the same apparatus after completing the coating step of the single layer, is sufficient. Thus not only is the processing time lowered with respect to that of EP 658103, because the pellets or beads do not need to be placed in a vacuum drier: at the same time the step of subjecting them to extreme temperatures of 80°C during 36 hours is avoided.

[0023] During the spraying process, the temperature to which the cores are subjected is 45°C, lower than the working temperature in EP 658103, and this is also a positive factor for controlling the chemical stability of the active principle and for avoiding the drawback, already commented in EP 658103, that high temperatures may accelerate drying of the beads, with the risk of formation of layers that are non-uniform and have high porosity.

[0024] During the coating process, the spraying speed is a factor to be considered in order to obtain a

higher efficiency in the process. In EP 658103 it is recommended to start with a low speed that is gradually increased along the process; it is even mentioned that a speed too high can cause an excessive moistening of the beads, resulting in agglomeration phenomena. On the contrary, if the speed is low product losses can occur due to drying of the spray itself. In EP 658103 the spraying speed at the beginning of the coating, for the obtention of the first layer, is about 600-700 g/min, and it is raised to 800 g/min once 30% of the coating solution has been consumed. This range of speeds is higher than those used in the present invention. The coating speed of the present invention is lower and is maintained constant throughout the whole process.

[0025] In the present invention the technology described in EP 658103 has been improved, since work is performed with inert cores of smaller size than those described in EP 658103, without causing agglomeration of the beads. On the other hand, spraying at lower speed is achieved with no product losses, and the drying of the final beads is carried out at lower working temperatures and reducing the drying process practically to the loading time.

[0026] The use of a single apparatus in which both the coating step, comprising only one layer, and the drying, allows for another advantage not only in cost but also in processing time, and this in its turn involves less handling of the final bead, with improvements of its chemical and physical integrity.

#### Example

[0027] 18.60 kg of methylene chloride and 10.00 kg of ethanol are mixed in a stainless steel container; then 0.98 kg of itraconazole, 1.32 kg of hydroxypropylmethylcellulose and 0.39 kg of poloxamer are introduced.

[0028] In the fluidized bed are introduced 2 kg of inert cores composed of saccharose (62.5%-91.5%) and starch (37.5%-8.5%), having a size of 500-600  $\mu\text{m}$ , and they are coated with the solution previously prepared, at a spraying speed of 30g/min and at a product temperature of 45°C. Once the coating step is finished, the charged cores are dried in the same apparatus during 15 minutes at 45°C.

#### Claims

1. An oral pharmaceutical composition in the form of a pellet, comprising a compound having antifungal activity as active principle selected between itraconazole and saperconazole, an inert core and a coating including said active principle, **characterised in that** said inert core has a particle size comprised between 50 and 600  $\mu\text{m}$  and **in that** said coating comprises a single layer obtained by spraying, on said inert core, a solution comprising said compound having antifungal activity, a hydrophilic poly-

mer and a non-ionic surfactant.

2. An oral pharmaceutical composition as claimed in claim 1, **characterized in that** said inert core has a particle size comprised between 500 and 600  $\mu\text{m}$ . 5
3. An oral pharmaceutical composition as claimed in claim 1, **characterized in that** said hydrophilic polymer is selected among the group comprising hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), polyvinyl pyrrolidone (PVP) and methacrylates. 10
4. An oral pharmaceutical composition as claimed in claim 1, **characterized in that** said non-ionic surfactant is selected from propylene glycol esters, glycerol esters, (mono, di, tri)acetylated sorbitan, (mono, di, tri)acetylated saccharose, polyoxyethylene sorbitan esters of fatty acids, polyoxyethylene alkyl ethers of fatty chain, polyoxyethylene-polyoxypropylene copolymers. 15 20
5. An oral pharmaceutical composition as claimed in any of the previous claims, **characterized in that** the proportions of hydrophilic polymer, non-ionic surfactant, active principle and inert core in the final pellet are, respectively: hydrophilic polymer (25%-60%), preferably (27%-55%), non-ionic surfactant (1%-15%), preferably (3%-10%), antifungal compound (19%-30%), preferably (20%-25%) and inert core (10%-45%), preferably (15%-43%). 25 30
6. An oral pharmaceutical composition as claimed in any of the previous claims, **characterized in that** the weight to weight ratio between the antifungal compound and hydrophilic polymer is [(1:1)-(1:3)] and between the antifungal compound and the surfactant is [(1.5:1)-(29:1)]. 35
7. A method for obtaining an oral pharmaceutical composition as claimed in any of the preceding claims, **characterized in that** the following steps are performed: 40
  - a) a coating, comprising a single layer, of the inert cores having a size between 50 and 600  $\mu\text{m}$ , by means of the spraying of a solution composed by the antifungal agent, the hydrophilic polymer and the non-ionic surfactant, at a constant coating speed throughout the a whole process; and 45
  - b) a single drying step of said coating in the same apparatus. 50

#### Patentansprüche

1. Orale pharmazeutische Zusammensetzung in

Form eines Granulats, umfassend eine Verbindung mit fungizider Aktivität als aktiven Grundbestandteil, ausgewählt aus Itraconazol und Saperconazol, einen inerten Kern und eine den aktiven Grundbestandteil aufweisende Beschichtung, **dadurch gekennzeichnet, dass** der inerte Kern eine Teilchengröße von 50 bis 600  $\mu\text{m}$  aufweist, und dass die Beschichtung eine einzige Schicht umfasst, erhalten durch Aufsprühen einer Lösung, welche die Verbindung mit fungizider Aktivität, ein hydrophiles Polymer und ein nicht-ionisches oberflächenaktives Mittel enthält, auf den inerten Kern.

2. Orale pharmazeutische Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** der inerte Kern eine Teilchengröße von 500 bis 600  $\mu\text{m}$  aufweist.
3. Orale pharmazeutische Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** das hydrophile Polymer aus der Gruppe ausgewählt ist, umfassend Hydroxypropylmethylcellulose (HPMC), Hydroxypropylcellulose (HPC), Polyvinylpyrrolidon (PVP) und Methacrylate.
4. Orale pharmazeutische Zusammensetzung nach Anspruch 1, **dadurch gekennzeichnet, dass** das nicht-ionische oberflächenaktive Mittel ausgewählt ist aus: Propylenglycolestern, Glycerinestern, (mono-, di-, tri-)acetyliertem Sorbitan, (mono-, di-, tri-)acetylierter Saccharose, Polyoxyethylensorbitanestern von Fettsäuren, Fettketten-Polyoxyethylenalkylethern, Polyoxyethylen-Polyoxypropylen-Copolymeren.
5. Orale pharmazeutische Zusammensetzung nach einem der vorhergehenden Ansprüche, **dadurch gekennzeichnet, dass** die Anteile des hydrophilen Polymers, des nicht-ionischen oberflächenaktiven Mittels, des aktiven Grundbestandteils und des inerten Kerns in dem endgültigen Granulat jeweils betragen: hydrophiles Polymer (25 % - 60 %), vorzugsweise (27 % - 55 %), nicht-ionisches oberflächenaktives Mittel (1 % - 15 %), vorzugsweise (3 % - 10 %), fungizide Verbindung (19 % - 30 %), vorzugsweise (20 % - 25 %) und inerte Kern (10 % - 45 %), vorzugsweise (15 % - 43 %).
6. Orale pharmazeutische Zusammensetzung nach einem der vorhergehenden Ansprüche, **dadurch gekennzeichnet, dass** Gewicht-zu-Gewicht-Verhältnis zwischen der fungiziden Verbindung und dem hydrophilen Polymer [(1:1) - (1:3)] beträgt und zwischen der fungiziden Verbindung und dem oberflächenaktiven Mittel [(1,5:1) - (29:1)]. 55
7. Verfahren zur Gewinnung einer oralen pharmazeutischen Zusammensetzung nach einem der vorher-

gehenden Ansprüche, **dadurch gekennzeichnet, dass** die folgenden Schritte durchgeführt werden:

- (a) eine Beschichtung, umfassend eine einzige Schicht, der inerten Kerne mit einer Größe von 50 bis 600 µm mittels Aufsprühen einer Lösung, welche aus dem fungiziden Mittel, dem hydrophilen Polymer und dem nicht-ionischen oberflächenaktiven Mittel aufgebaut ist, mit einer konstanten Beschichtungsgeschwindigkeit während des gesamten Prozesses; und
- (b) eine einziger Trocknungsschritt der Beschichtung in der gleichen Vorrichtung.

## Revendications

1. Composition pharmaceutique orale sous la forme d'un comprimé, comprenant un composé ayant une activité antifongique en tant que principe actif sélectionné entre l'itraconazole et le saperconazole, un coeur inerte et un enrobage comprenant ledit principe actif, **caractérisé en ce que** ledit coeur inerte présente une taille particulière comprise entre 50 et 600 µm et **en ce que** ledit enrobage comprend une couche unique obtenue en pulvérisant, sur ledit coeur inerte, une solution comprenant ledit composé ayant une activité antifongique, un polymère hydrophile et un tensioactif non ionique.
2. Composition pharmaceutique orale selon la revendication 1, **caractérisée en ce que** ledit coeur inerte présente une taille particulière comprise entre 500 et 600 µm.
3. Composition pharmaceutique orale selon la revendication 1, **caractérisée en ce que** ledit polymère hydrophile est sélectionné parmi le groupe comprenant l'hydroxypropylméthylcellulose (HPMC), l'hydroxypropylcellulose (HPC) la polivinylpyrrolidone (PVP) et des méthacrylates.
4. Composition pharmaceutique orale selon la revendication 1, **caractérisée en ce que** ledit tensioactif non ionique est sélectionné parmi des esters de propylène glycol, des esters de glycérol, du sorbitan (mono, di, tri)acétylé, du saccharose (mono, di, tri) acétylé, des esters de polyoxyéthylène de sorbitan d'acides gras, des éthers de polyoxyéthylène d'alkyle à chaîne grasse et de copolymères de polyoxyéthylène-polyoxypropylène.
5. Composition pharmaceutique orale selon l'une quelconque des revendications précédentes, **caractérisée en ce que** les proportions de polymère hydrophile, de tensioactif non ionique, de principe actif et de coeur inerte dans le comprimé final sont, respectivement : polymère hydrophile (25 % à 60

%), de préférence (27 % à 55 %), tensioactif non ionique (1 % à 15 %), de préférence (3 % à 10 %), composé antifongique (19 % à 30 %), de préférence (20 % à 25 %) et partie centrale (10 % à 45 %), de préférence (15 % à 43 %).

6. Composition pharmaceutique orale selon l'une quelconque des revendications précédentes, **caractérisée en ce que** le rapport poids/poids entre le composé antifongique et le polymère hydrophile est [(1:1)-(1:3)] et entre le composé antifongique et le tensioactif est [(1,5:1)-(29:1)].
7. Procédé pour obtenir une composition pharmaceutique orale selon l'une quelconque des revendications précédentes, **caractérisé en ce que** les étapes suivantes sont effectuées :

- a) application d'un enrobage, comprenant une couche unique, sur les coeurs uniques ayant une taille comprise entre 50 et 600 µm, au moyen de la pulvérisation d'une solution composée de l'agent antifongique, du polymère hydrophile et du tensioactif non ionique, à une vitesse d'enrobage constante tout le long du procédé ; et
- b) une étape de séchage unique dudit enrobage dans le même appareil.